Search Results

Search Results

Research Study Search Results

Return to Search Form
  1. Cancer (Oncology)

    1. Psychoeducation for Spouses of Women with Breast Cancer Frances M. Lewis, PhD, RN, FAAN (University of Washington)
    1. Breast

      1. SWOG 1207: Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer – e3 Breast Cancer Study Gary Goodman, M.D.
      2. SWOG 1202: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer Gary Goodman, M.D.
      3. SWOG 1007: A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less Gary Goodman, M.D.
      4. NSABP B-50-I (Katherine): Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with HER2+ Primary Breast Cancer Who have Residual Tumor Present Pathologically in the Breast or Axillary lymph Nodes Following Preoperative Therapy Tanya Wahl, M.D.
      5. E2112 :A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer Gary Goodman, M.D.
      6. CTSU E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Christine Lee, M.D.
      7. CRC 14117: Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC) Erin D. Ellis, MD
      8. CRC 14055: A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Henry Kaplan, MD
      9. CRC 14034: A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer Erin Ellis, M.D.
      10. CRC 13105: A Randomized Phase 2 Study of Veliparib plus Temozolomide or Veliparib plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer Erin Ellis, M.D.
      11. CRC 10016: I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) Erin Ellis, M.D. and Henry Kaplan, M.D.
      12. Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence Henry Kaplan, MD
    2. Cancer Detection Program

      1. Ovarian Cancer Early Detection Program Pamela Paley, M.D.
      2. Flight Attendants Medical Research Institute (FAMRI) – International Early Lung Cancer Action Program (IELCAP) Protocol Ralph Aye, M.D.
    3. Colon

      1. SWOG 0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III Gary Goodman, M.D.
      2. CTSU C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer Gary Goodman, M.D.
    4. Colorectal

      1. Endometrial

        1. Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery Pamela Paley, M.D.
      2. Esophageal

        1. CTSU R1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma Gary Goodman, M.D.
      3. Gallbladder or Bile Duct

        1. Kidney

          1. SWOG 0931: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Gary Goodman, M.D.
        2. Leukemia

          1. CRC 13084: Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission Michael Milder, M.D.
        3. Liver

          1. CRC 13091: A Phase III, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib Philip Gold, M.D.
        4. Lung

          1. SWOG 1206: A Dose Finding Study Followed by Phase II Randomized Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Gary Goodman, M.D.
          2. SWOG 0905: Randomized Phase II Study of Cediranib (NSC #732208) Versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma Gary Goodman, M.D.
          3. CTSU C140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<=2 cm) Peripheral Non-Small Cell Lung Cancer Gary Goodman, M.D.
          4. CRC 14072: A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) Howard (Jack) West, M.D.
          5. CRC 14050: An Open Registry to Measure the Impact of Adding RNA Expression Testing on Referral Decisions in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients Eric Vallieres, M.D.
          6. CRC 14035: An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations Howard (Jack) West, M.D.
          7. CRC 14016: A Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer Stage IIIB, Stage IV or recurrent Howard (Jack) West, M.D.
          8. CRC 14015: Phase 3 Randomized, Placebo-Controlled, Double-blind, Multi-Center, Two-Part Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) Howard (Jack) West, M.D.
          9. CRC 14014: A Phase 3, Multicenter, Randomized, Open‐Label Cross-Over Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell NSCLC Howard (Jack) West, M.D.
          10. CRC 14012: Phase II Study of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR-TKI Howard (Jack) West, M.D.
          11. CRC 13107: Double-Blind, Randomized, Placebo-Controlled Study of Selumetinib in Combination with Docetaxel, in Patients receiving second line treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (SELECT-1) Howard (Jack) West, M.D.
          12. CRC 13086: A Study of Heat Shock Protein 90 (HSP90) Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-Small Cell Lung Cancer (NSCLC) Howard (Jack) West, M.D.
          13. CRC 13049: Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib Howard (Jack) West, M.D.
          14. A Phase II Multi-Center Study of the Tolerability of Weekly Nab-Paclitaxel as Second Line Treatment for Elderly Patients with Advanced Lung Cancer Howard (Jack) West, M.D.
        5. Multiple Myeloma

          1. CRC 13160: A Placebo-Controlled Study of Oral L-glutamine and Pyridoxal-5-phosphate (Vitamin B6) for the mitigation of Velcade-Induced Peripheral Neuropathy: A Pilot Study Michael Milder, M.D.
          2. CRC 13051: Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Michael Milder, M.D.
        6. Prostate

          1. SWOG 1216: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer Gary Goodman, M.D.
          2. CTSU A031201: Phase III Trial of Enzalutamide versus Enzalutamide Abiraterone and Prednisone For Castration-Resistant Metastatic Prostate Cancer Gary Goodman, MD
        7. Rectal

          1. CTSU N1048: Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision Gary Goodman, M.D.
      4. End of Life

        1. Reducing Health Disparities at End-of-Life Ardith Doorenbos, PhD, RN
        1. Heart & Vascular

          1. Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery John Petersen II, MD
          1. Cardiac Surgery

            1. Surgical Treatment for atrial Arrhythmia Registry (STAR2 Maze IV Outcomes) Glenn R. Barnhart, MD
            2. RED CELL STORAGE DURATION STUDY (RECESS) Samuel John Youssef, MD
            3. Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management (NACHO) Lori Beth Heller, MD
            4. Multi-Center Experience with the Rapid Deployment EDWARDS INTUITY Valve System for Aortic Valve Replacement (TRANFORM Trial) Eric Lehr, MD PhD FRCSC
            5. AtriCure Synergy RF Energy Lesions For Non-Paroxysmal Forms Of Atrial Fibrillation Treatment During Concomitant On-Pump Cardiac Surgery Post-Approval Study (or “ABLATE PAS”) Glenn R. Barnhart, MD
          2. Electrophysiology

            1. VICTORY AF. A Phase 2,Proof of Concept,Randomized,Placebo-Controlled,Parallel Group Study to Evaluate the Effect of Ranolazine & Dronedarone When Given Alone and in Combination on Atrial Fibrillation Burden in Subjects with Paroxysmal Atrial Fibrillation Darryl Wells, MD
            2. VICTORY AF Darryl Wells, MD
            4. Clinical Evaluation of the Blazer Open-Irrigated Radiofrequency Ablation Catheter for the Treatment of Type 1 Atrial Flutter – BLOCK-CTI Darryl Wells, MD
            5. CABANA Study Darryl Wells, MD
            6. A Randomized, Open-label, Active-controlled Multi-center Study to Evaluate the Safety of Rivaroxaban and Vitamin K Antagonists in Subjects Undergoing Catheter Ablation for Atrial Fibrillation (VENTURE-AF) Darryl Wells, MD
          3. Interventional Cardiology Trials

            1. TRYTON Mark Reisman, MD
            2. Early Recognition & Treatment of STEMI - Angel Medical Systems Guardian implant to detect ST shifts and other cardiac irregularities and alert subject to seek medical attention (ALERTS) Jeffrey Westcott, MD
            3. Continued Access to PREVAIL (CAP2) Mark Reisman, MD
            4. COLOR Observational Registry John Petersen II, MD
            5. A Pivotal Trial to Establish Efficacy and Long-Term Safety of the Parachute Implant System Mark Reisman, MD
            6. A Clinical Evaluation of the Safety and Effectiveness of the MitraClip® System for the Treatment of Functional Mitral Regurgitation in Symptomatic Subjects who are Extremely High Risk for Mitral Valve Surgery Mark Reisman, MD
            7. A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions Robert Bersin, MD
          4. Other Trials

            1. Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation. John Petersen II, MD
            2. REAL-ICU Sandeep Sachdeva, MD
            3. Patient and Partner Intervention to Improve Outcomes After an Implantable Cardioverter Defibrillator (ICD) Cynthia M. Dougherty, ARNP PhD
          5. Peripheral Trials

            1. A clinical trial to evaluate the safety and effectiveness of the Absolute Pro® (and Absolute Pro® LL) Peripheral Self-Expanding Stent Systems in the treatment of atherosclerotic or restenotic lesions in the femoral and popliteal arteries (MOMENTUM) Robert Bersin, MD
          6. Pharma Clinical Trials

            1. CANTOS- Phase 3, randomized, double-blind, placebo controlled study of quarterly injections of canakinumab Paul Huang, MD
          7. Structural Heart Trials

            1. Percutaneous Mitral Valve Repair – Continued Access Registry for the Evalve Inc. MitraClip system for patients with 3+/4+ mitral regurgitation. (REALISM) Mark Reisman, MD
            2. Left Atrial Appendage Closure for Atrial Fibrillation – PREVAIL Mark Reisman, MD
            3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Transendocardial Injection Of Ixmyelocel-T In Subjects With Heart Failure Due To Ischemic Dilated Cardiomyopathy. Paul Huang, MD
          8. Vascular Surgery

            1. Comparison of Safety and Primary Patency Between FUSION Vascular Graft with Bioline and Exxcel ePTFE Kaj Johansen, MD
        2. Kidney/Dialysis

            1. Kidney Transplant

              1. Observational registry study to determine if enrollment in a regional kidney paired donor exchange program improves the overall rate of kidney transplantation in sensitized patients, and sensitized patients undergoing desensitization treatments Lisa Florence, M.D.
              2. Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression Nelson Goes, M.D.
              3. Evaluating Nulojix Long-Term Safety in Transplant Nelson Goes, M.D.
              4. A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor Lisa Florence, M.D.
            2. Other

              1. Hemodialysis Fistual Maturation Consortium Study Jonathan Himmelfarb, MD
          1. Liver

              1. AILD

                1. A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD) Marquis E Hart, MD
              2. Hepatic Impairment

                1. Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2 Kris Kowdley, MD
                2. CENTAUR Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis Kris Kowdley, MD
                3. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Primary Sclerosing Cholangitis Kris Kowdley, MD
                4. A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of Subjects with Chronic Hepatitis C and Decompensated Cirrhosis or Post-Liver Transplant Subjects with Chronic Hepatitis C Recurrence Anne Larson, MD
            1. Macular Degeneration

              1. Study of the Efficacy and Safety of a Drug for Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration Craig G. Wells, M.D.
              1. Neuroscience

                  1. Brain Tumor

                    1. Safety and Tolerability of TPI-287 in Adults with Recurrent Glioblastoma Who Have Progressed After Treatment with Avastin® Tara Benkers, MD
                    2. Safety and Tolerability of TPI-287 in Adults with Recurrent Glioblastoma Who Have Not Been Previously Treated with Avastin® Tara Benkers, MD
                    3. Open label trial of Nivolumab versus Avastin® in adults with recurrent GBM who have not been previously treated with Avastin®. Tara Benkers, MD
                    4. An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma (The “ACT IV” Study) John Henson, MD
                    5. A Study to Evaluate the Safety and Feasibility of Transcranial MRI-Guided Focused Ultrasound Surgery in the Treatment of Brain Tumors. Stephen Monteith, MD
                    6. A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM John Henson, MD
                    7. A Phase III Clinical Trial Evaluating DCVax®-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme Charles Cobbs, MD
                  2. Brain Tumor /Neurosurgery

                    1. The Comprehensive Neuro-Oncology Data Repository (CONDR): Prospective Collection of Clinical Tissue and Imaging Data for the Study of Patients with Brain Tumors. Sarah C. Jost, MD
                  3. Craniotomy /Interventional

                    1. Intravenous acetaminophen for craniotomy patients Arthur M. Lam, M.D.
                  4. Epilepsy

                    1. Tissue Procurement and Repository for Future Neuroscience Studies Ryder Gwinn, MD
                  5. Epilepsy /Genetic

                    1. Protocol For Research of Genetic Epilepsy Marcio Sotero de Menezes, MD
                  6. Growth Hormone Deficiency

                    1. A phase 3, multicenter study designed to evaluate the efficacy and safety of a long-acting hGH product (MOD-4023) in adult subjects with growth hormone deficiency Kevin Yuen, MD
                  7. Movement Disorders

                    1. A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects. Ryder Gwinn, MD
                    2. Gamma Knife Thalamotomy for Treatment of Essential Tremor Christopher Loiselle, M.D.
                  8. Multiple Sclerosis

                    1. The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO) Peiqing Qian, MD
                    2. Quantitative imaging of whole and gray matter demyelination in multiple sclerosis using macromolecular proton fraction mapping. James Bowen, MD
                    3. JCV Antibody Program in patients with Relapsing MS and who are Receiving or Considering Treatment with Tysabri Lily Jung, MD
                    4. Ibudilast versus placebo in subjects with progressive multiple sclerosis Pavle Repovic, MD
                    5. Effectiveness of DMF and its impact on PROs in Suboptimal GA Responders with RMS (RESPOND) Pavle Repovic, MD
                    6. A Phase 4 Multicenter, Open-Label, Single Arm study to evaluate switching from BRACET/Gilenya to Natalizumab in subjects with relapsing forms of Multiple Sclerosis(MS). Pavle Repovic, MD, PhD
                    7. A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis James Bowen, MD
                    8. A Multicenter Randomized Open-Label Study to Assess the Impact of Natalizumab Versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects (REVEAL). Peiqing Qian, MD
                    9. A 12-month, randomized, blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with multiple sclerosis. Lily Jung Henson, MD
                    10. 101MS402 TYGRIS - Tysabri Global Observational Program in Safety Lily Jung, MD
                  9. Neuromyelitis Optica (NMO)

                    1. A randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of Eculizumab in patients with relapsing neuromyelitis optica (NMO) Pavle Repovic, MD
                  10. Neuro-Ophthalmology

                    1. Eli Lilly NAION Steven Hamilton, MD
                  11. Parkinson's Disease

                    1. A feasibility study to evaluate safety and initial effectiveness of Exablate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease. Ryder Gwinn, MD
                  12. Pituitary Tumor /Acromegaly

                    1. An acromegaly, open-label, multi-center, safety monitoring program for treating patients with SOM230 (pasireotide) LAR who have need to receive medical therapy (ACCESS) Kevin Yuen, MD
                  13. Spine

                    1. RELIEF - A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain Ryder Gwinn, MD
                  14. Stroke

                    1. Randomized, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of dabigatran etexilate versus aspirin in patients with embolic stroke of undetermined source. Sheila Smith, MD
                    2. MISTIE III - Treatment of intracerebral hemorrhage. David Newell, MD
                    3. A phase IIIb double-blind multicenter study to evaluate the efficacy and safety of Alteplase in patients with mild stroke: rapidly improving symptoms and minor neurologic deficits (PRISMS) Aaron Stayman, MD
                1. Ophthalmology

                  1. Study of the Efficacy and Safety of a Drug for Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration Craig G. Wells, M.D.
                  1. Perinatal Studies

                      1. Perinatal Research

                        2. Omega Study - Epidemiology of Marine Fatty Acids and Preeclampsia (CLOSED TO ENROLLMENT; FOLLOW-UP ONGOING) Michelle Williams, ScD
                        3. Epidemiology of Abruptio Placentae in Peru (ENROLLMENT CLOSED; DATA ANALYSIS ONLY) Michelle Williams, ScD
                    1. Rheumatology

                        1. Ankylosing Spondylitis

                          1. Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis Philip J. Mease, MD
                        2. Axial Spondyloarthritis

                          1. A Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects with Non-Radiographic Axial Spondyloarthritis. Philip J. Mease, MD
                        3. Fibromyalgia

                          1. Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301 (PERRFECT-301)
                        4. Osteoarthritis

                          1. A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis Philip J. Mease, MD
                        5. Osteoporosis

                          1. Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures. Christopher Shuhart, MD, MHA
                        6. Psoriatic Arthritis

                          1. Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors (OPAL BEYOND) Philip J. Mease, MD
                          2. Study of Efficacy, Safety and Effect on Radiographic Progession of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-1) Philip J. Mease, MD
                          3. Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis (AMVISION-2) Philip J. Mease, MD
                          4. Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis (OPAL BALANCE) Philip J. Mease, MD
                          5. Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Philip J. Mease, MD
                          6. Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (OPAL BROADEN) Philip J. Mease, MD
                          7. Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis (ASTRAEA) Philip J. Mease, MD
                        7. Rheumatoid Arthritis

                          1. Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients (DARWIN3) Philip J. Mease, MD
                          2. Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Patients (DARWIN1) Philip J. Mease, MD
                          3. A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate Philip J. Mease, MD
                          4. A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy Philip J. Mease, MD
                        8. Systemic Lupus Erythematosis (SLE)

                          1. Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY 2) Philip J. Mease, MD
                          2. A study of the effectiveness and safety of Epratuzumab in Systemic Lupus Erythematosis (SLE) (EMBODY) Philip J. Mease, MD
                      1. Sleep Medicine

                          1. Sleep Apnea

                            1. Effects of Inspire Implantable Nerve Stimulation System on Obstructive Sleep Apnea. Sarah Stolz, MD
                        1. Thoracic

                          1. A Prospective Controlled Post-Approval Study of NeoMend ProGEL™ Pleural Air Leak Sealant in the Treatment of Visible Pleural Air Leaks After Standard Pleural Closure Eric Vallieres, M.D.
                          2. A Post-Approval Study of the LINX® Reflux Management System Brian Louie, M.D.